Nebulized LAMA therapy for COPD
MAGNAIR® Nebulizer System with eFlow® technology features a vibrating, perforated membrane in a closed-system device
- Delivers nebulized LAMA in 2 to 3 minutes, with proper setup and cleaning1,2
- A closed-system device featuring eFlow technology3*
- Requires a patient's natural tidal breathing, allowing for inhalation independent of inspiratory flow4
- No hand/breath coordination, deep breaths, or breath-holding is required; multiple steps required for device setup and cleaning4
*The eFlow Closed System is part of PARI's electronic nebulizer platform. It features a vibrating, perforated membrane with laser-drilled holes that is designed to deliver consistently sized particles and to nebulize the solution for administration.3,5

Please see Important Safety Information below.
COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist.
References:
- LONHALA MAGNAIR [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2018.
- LONHALA MAGNAIR [instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2017.
- Pham S, Ferguson GT, Kerwin E, et al. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution [published online ahead of print November 10, 2017]. J Aerosol Med Pulm Drug Deliv. doi:10.1089/jamp.2017.1384.
- Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72.
- PARI eFlow® Technology Device Comparison Chart. Foundation Care Pharmacy. https://www.foundcare.com/wp-content/uploads/2016/08/fnc_device_chart.pdf. Accessed January 25, 2018.